Christina M. Annunziata, Ph.D.
Affiliations: | 2000 | Georgetown University Medical Center, Washington, DC, United States |
Area:
Molecular Biology, OncologyGoogle:
"Christina Annunziata"Parents
Sign in to add mentor| Jeffrey Cossman | grad student | 2000 | Georgetown University Medical Center | |
| (CD40 signaling in Hodgkin's disease.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Eskander RN, Moore KN, Monk BJ, et al. (2023) Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Frontiers in Oncology. 13: 1258228 |
| Harrington BS, Kamdar R, Ning F, et al. (2023) UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer. Journal of Experimental & Clinical Cancer Research : Cr. 42: 270 |
| Shibuya Y, Kudo K, Zeligs KP, et al. (2023) SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-α Autocrine Signaling. Cancers. 15 |
| Tsang KY, Fantini M, Mavroukakis SA, et al. (2022) Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas. Cancers. 14 |
| Caminear MW, Harrington BS, Kamdar RD, et al. (2022) Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells. Frontiers in Oncology. 12: 762820 |
| Hernandez LF, Dull AB, Korrapati S, et al. (2021) Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism. Cell Death Discovery. 7: 134 |
| Ning F, Cole CB, Annunziata CM. (2020) Driving Immune Responses in the Ovarian Tumor Microenvironment. Frontiers in Oncology. 10: 604084 |
| Walcott FL, Wang PY, Bryla CM, et al. (2020) Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome. Jnci Cancer Spectrum. 4: pkaa063 |
| Noonan AM, Cousins A, Anderson D, et al. (2020) Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer. Cancers. 12 |
| Lee JM, Annunziata CM, Hays JL, et al. (2020) Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. Gynecologic Oncology |